The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab (BV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
Amreen Husain
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Yan V. Wang
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Rikke Frederiksen
Employment or Leadership Position - Roche
Stock Ownership - Roche
David T. Bollag
Employment or Leadership Position - Roche
Stock Ownership - Roche
Lars Christian Hanker
No relevant relationships to disclose
Belen Ojeda
No relevant relationships to disclose
Maarit Anttila
Consultant or Advisory Role - Roche
Enrico Breda
No relevant relationships to disclose
Peter Vuylsteke
No relevant relationships to disclose
Eric Pujade-Lauraine
Honoraria - Roche